Key points
- FY26 revenue increased by 145% to $12.0 million
- FY26 loss improved by 25% to $7.5 million
- Raised $30 million through an Entitlement Offer
- Continued investment in DEP® pipeline
- CEO highlights advancements in radiopharmaceutical asset
Full summary
Starpharma Holdings Ltd announced its Annual Report and full-year financial results for the year ended 30 June 2026. The biotechnology company reported a substantial 145% increase in revenue to $12.0 million, driven by the $8.3 million upfront payment from the Genentech licence agreement. The company's reported loss improved by 25% to $7.5 million. Post-year-end, Starpharma raised net proceeds of $30 million through a widely supported Entitlement Offer, extending its funding runway into FY28. Research and product development expenditure increased to $11.1 million. Starpharma's CEO, Cheryl Maley, emphasized the company's advancements in its lead radiopharmaceutical asset and strategic partnerships, with a focus on targeted oncology treatments.
Guidance
FY26 revenue: $12.0 million, FY26 loss: $7.5 million, FY26 R&D expenditure: $11.1 million
Outlook
Starpharma aims to build long-term shareholder value through the development of targeted oncology therapies enabled by its DEP® technology, with a focus on executing milestones and translating scientific and commercial progress into meaningful outcomes.